SCA
LGND icon

Summit Creek Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Summit Creek Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-119,940
Closed -$7.44M – 68
2020
Q4 		$7.44M Sell
119,940
-6,668
-5% -$380K 0.95% 48
2020
Q3 		$7.53M Sell
126,608
-11,926
-9% -$814K 1.12% 42
2020
Q2 		$9.67M Buy
138,534
+25,391
+22% +$1.61M 1.42% 35
2020
Q1 		$5.13M Sell
113,143
-609
-0.5% -$34.5K 1.03% 42
2019
Q4 		$7.4M Sell
113,752
-641
-0.6% -$42.8K 1.16% 45
2019
Q3 		$7.1M Buy
114,393
+4,200
+4% +$264K 1.19% 38
2019
Q2 		$7.85M Buy
110,193
+33,935
+45% +$2.5M 1.32% 37
2019
Q1 		$5.98M Sell
76,258
-128
-0.2% -$9.7K 1.07% 43
2018
Q4 		$6.47M Buy
76,386
+31,347
+70% +$3.34M 1.31% 42
2018
Q3 		$7.71M Sell
45,039
-35,731
-44% -$5.39M 1.24% 42
2018
Q2 		$10.4M Sell
80,770
-7,534
-9% -$841K 1.87% 25
2018
Q1 		$9.1M Buy
88,304
+20,053
+29% +$1.98M 1.65% 31
2017
Q4 		$5.83M Sell
68,251
-505
-0.7% -$43.8K 1.09% 46
2017
Q3 		$5.84M Sell
68,756
-521
-0.8% -$41.3K 1.15% 42
2017
Q2 		$5.25M Sell
69,277
-5,699
-8% -$399K 1.08% 46
2017
Q1 		$4.95M Sell
74,976
-23,844
-24% -$1.57M 1.04% 44
2016
Q4 		$6.26M Sell
98,820
-140,703
-59% -$8.88M 1.07% 42
2016
Q3 		$15.3M Buy
239,523
+49,933
+26% +$3.67M 2.5% 15
2016
Q2 		$14.1M Sell
189,590
-12,704
-6% -$943K 2.4% 18
2016
Q1 		$13.5M Buy
202,294
+73,998
+58% +$4.5M 2.13% 25
2015
Q4 		$8.68M Buy
128,296
+15,073
+13% +$931K 1.45% 36
2015
Q3 		$6.05M Buy
+113,223
New +$6.87M 0.98% 45

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Summit Creek Advisors's LGND Position: Q1 2021 in Review

Summit Creek Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2021, closing a stake of 119,940 shares — an estimated $7.44M sold.

Summit Creek Advisors first reported a position in LGND in Q3 2015 and held it in 22 quarters. The position peaked at $15.3M in Q3 2016. 228 funds tracked by Wall St. Rank hold LGND as of Q1 2021.

  • Summit Creek Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Summit Creek Advisors sold 119,940 Ligand Pharmaceuticals shares in Q1 2021, an estimated $7.44M.
  • Summit Creek Advisors first reported a position in Ligand Pharmaceuticals in Q3 2015 and held it in 22 quarters.
  • Summit Creek Advisors's Ligand Pharmaceuticals position peaked at $15.3M in Q3 2016.
  • 228 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2021.

Based on Summit Creek Advisors's 13F filing for Q1 2021, filed 20 Apr 2021.